Thylakoids for Health & Longevity
Evidence Review created on 09/26/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Thylakoid Membranes, Spinach Thylakoids, Thylakoid-Rich Spinach Extract, Green-Plant Membranes, Chloroplast Membranes, Appethyl, Thykamine
Motivation
Thylakoids are the stacked internal membranes inside the green, light-capturing compartments of plant leaf cells, where photosynthesis turns sunlight into chemical energy. Concentrated from spinach and sold as a powdered supplement, they attract interest as a food-derived way to curb hunger and cravings: in the gut they slow the digestion of dietary fat, which prolongs the body’s own fullness signals.
Spinach thylakoid extracts were developed at a Swedish university in the 2000s and reached the market as appetite-control ingredients in powders, capsules and snack bars. Their headline appeal comes from short human studies describing less hunger and fewer cravings for sweet and salty snacks after a single dose, which raised the question of whether this could translate into lasting changes in body weight.
This review examines what the human evidence shows about thylakoid supplementation for appetite, body weight and metabolic health in health-focused adults, how strong and how independent that evidence is, which risks and interactions are known, and how the extract is used in practice.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section lists an in-depth magazine feature and narrative reviews that explain how thylakoid supplements are thought to work and what the human studies found.
-
Stop Unhealthy Food Cravings - Michael Downey
Plain-language feature on the single-day craving trial and the 12-week weight trial; Life Extension sells a thylakoid-containing product, a direct financial interest in favorable framing.
-
The Use of Green Leaf Membranes to Promote Appetite Control, Suppress Hedonic Hunger and Loose Body Weight - Erlanson-Albertsson & Albertsson, 2015
Overview by the Lund developers of the extract, commercialized by Greenleaf Medical AB, covering fat-digestion delay, gut-hormone release, reward-driven eating and gut bacteria; the authors have a commercial interest.
-
Gut fat signaling and appetite control with special emphasis on the effect of thylakoids from spinach on eating behavior - Rebello et al., 2015
Explains how fat sensed in the gut signals fullness to the brain and where thylakoids fit, written by Louisiana obesity researchers outside the Swedish developer group.
-
Thylakoids: A Novel Food-Derived Supplement for Obesity - A Mini-Review - Foshati & Ekramzadeh, 2020
Independent Iranian mini-review summarizing animal and human findings on satiety, weight, blood sugar, blood fats, inflammation and gut bacteria, while noting how few well-designed studies exist.
Of the priority experts, only Life Extension is included. FoundMyFitness (Rhonda Patrick) offers only brief one-line news links on thylakoid studies without discussion, Andrew Huberman’s podcast discusses thylakoids only in a roughly one-minute segment of an episode with Dr. Casey Means, too brief to qualify, and searches of Peter Attia, Chris Kresser and Lifespan.io found no thylakoid content. Four items are listed because no further in-depth sources qualified.
Grokipedia
Encyclopedic entry on thylakoid structure, sugar-bearing membrane fats and photosynthetic protein complexes, the components that bind dietary fat and digestive enzymes in supplement research; it covers plant biology, not human use.
Examine
Thylakoids benefits, dosage, and side effects
Brief Examine page by Kamal Patel defining thylakoids as the light-trapping structures of plants, with trial summaries in a members-only research feed; the free page gives no dosage or effect conclusions.
ConsumerLab
No dedicated ConsumerLab article on thylakoids exists as of September 26, 2026; the site’s search returns only a general members-only answer on natural appetite suppressants in which the term may appear.
Systematic Reviews
This section lists the systematic reviews and meta-analyses of thylakoid supplementation found on PubMed.
-
Thylakoid supplementation and hunger and fullness perception: a systematic review and dose-response meta-analysis of randomized controlled trials - Nikrad et al., 2025
Pools 5 randomized trials: thylakoids modestly lowered hunger and raised fullness, most clearly within 8 weeks; body weight and safety were not analyzed.
-
Effects of thylakoid intake on appetite and weight loss: a systematic review - Amirinejad et al., 2020
Qualitative review of 8 human trials: consistent short-term hunger and satiety-hormone effects but conflicting weight results; most included trials came from the developer group.
No systematic review or meta-analysis of thylakoid safety or adverse effects exists on PubMed as of September 26, 2026; the risk side of the trade-off is unrepresented.
Mechanism of Action
Thylakoids are membrane sheets made mostly of protein (about 70%), plus galactolipids (sugar-bearing membrane fats), chlorophyll, carotenoids and vitamin K1. Taken orally, they are not absorbed; they act inside the gut and are then digested or fermented by gut bacteria.
- Slower fat digestion: the membranes coat fat droplets and bind pancreatic lipase and colipase (the enzyme pair that splits dietary fat), slowing rather than blocking fat breakdown (Albertsson et al., 2007). Unlike orlistat (a lipase-inhibitor weight-loss drug), they do not cause fatty stools.
- Satiety hormones: fat reaching the lower small intestine releases more cholecystokinin (CCK, a gut hormone signaling fullness) while ghrelin (the “hunger hormone”) falls (Köhnke et al., 2009); glucagon-like peptide-1 (GLP-1, a gut hormone that curbs appetite and slows stomach emptying) rises (Montelius et al., 2014).
- Reward signaling: GLP-1 also acts on brain reward circuits, the proposed basis for fewer cravings.
- Gut transit and bacteria: in rats, thylakoids slowed stomach emptying; in people, they shifted gut bacteria without fatty stools (Stenblom et al., 2016).
Competing view: the European Food Safety Authority (EFSA), a public regulator without commercial stake, found no plausible mechanism for a sustained weight effect (EFSA Panel, 2023), and acute satiety faded within 4 hours (Rebello et al., 2015).
Pharmacology: being non-absorbed, thylakoids have no blood half-life, receptor selectivity or cytochrome P450 (CYP, the liver’s main drug-metabolizing enzymes) metabolism; activity lasts only while the dose is in the gut. Heating above 60 °C degrades function (Östbring et al., 2014).
Historical Context & Evolution
Thylakoids are the photosynthetic machinery of green plants and have always been eaten in leafy vegetables, though largely locked inside indigestible cell walls. Supplement use began at Lund University, Sweden, where biochemist Per-Åke Albertsson, a long-time photosynthesis researcher, and appetite researcher Charlotte Erlanson-Albertsson found that biological membranes inhibit fat-digesting enzymes and reduce food intake in rats (Albertsson et al., 2007).
Human single-meal studies followed from 2009, then a 12-week trial in overweight women reporting extra weight loss and fewer cravings (Montelius et al., 2014). Greenleaf Medical AB commercialized the extract as Appethyl and funded or co-authored much of the later work.
In 2023, EFSA reviewed the manufacturer’s claim, noting the 12-week trial lost significance on re-analysis and an unpublished trial gave only 0.6–1.2% extra loss, and concluded that a cause-and-effect relationship with weight loss was not established (EFSA Panel, 2023); EFSA is a public regulator whose panel members derive no revenue from the verdict. A Danish trial in prediabetes stopped in 2023 when the manufacturer suspended funding (NCT05095038). Independent Iranian trials reported added fat loss in women with a hormonal disorder (Tabrizi et al., 2020), but no extra fat loss over exercise alone in men (Abbassi-Daloii et al., 2025). The short-term appetite effect is replicated; the long-term weight effect remains open. In parallel, a Canadian company developed a thylakoid extract as an anti-inflammatory skin drug (Lynde et al., 2022), and laboratories began engineering “nanothylakoids” to supply energy to animal cells (Chen et al., 2022).
Expected Benefits
High 🟩 🟩 🟩
Reduced Hunger, Greater Fullness and Fewer Cravings
Taken with a meal, thylakoids lower hunger, raise fullness and dampen cravings for sweet, salty and fatty snacks for several hours. A meta-analysis pooled 5 randomized controlled trials (RCTs) rated on visual analog scales (VAS, 0–100 mm rating lines) (Nikrad et al., 2025); single-day trials in overweight women (Stenblom et al., 2015) and adults (Rebello et al., 2015) agree. Most trials involved the developers, and intake at the next meal did not fall.
Magnitude: Pooled hunger fell by 2.4 mm and fullness rose by 4.6 mm on a 100 mm scale (weighted mean difference, WMD, the average gap between groups); one single-dose trial (Stenblom et al., 2015) reported 21% less hunger and 36% fewer snack cravings across the day.
Medium 🟩 🟩
Clearer Skin in Eczema With a Topical Thylakoid Cream
A thylakoid-based cream (Thykamine) improved mild-to-moderate atopic dermatitis (eczema) in a 4-week phase 2 RCT (Lynde et al., 2022) that enrolled 162 adults per its registry entry (NCT03540043). Only the 0.10% strength met the primary endpoint, and adverse events matched the inert cream. The developer sponsored the trial, and the effect concerns skin application, not oral supplements.
Magnitude: 30.8% vs 6.7% reached clear or almost-clear skin on the Investigator’s Global Assessment (IGA, a clinician’s 5-point severity score) at day 29 with the 0.10% cream.
Low 🟩
Greater Weight and Fat Loss ⚠️ Conflicted
RCTs found added loss in overweight women (Montelius et al., 2014) and obese women with polycystic ovary syndrome (PCOS, a hormonal disorder) (Tabrizi et al., 2020). The first lost significance on re-analysis; EFSA (no revenue at stake) rejected the claim (EFSA Panel, 2023). Net reading: modest, diet-dependent loss.
Magnitude: An extra 1.5 kg (5.0 vs 3.5 kg) over 12 weeks in overweight women, and an extra 3.8 kg of weight (7.0 vs 3.2 kg) and 3.8 kg of fat in obese women with PCOS; an unpublished 12-week trial reviewed by EFSA found only 0.6–1.2% of body weight.
Lower Fasting Insulin and Insulin Resistance ⚠️ Conflicted
With calorie restriction, thylakoids lowered fasting insulin and HOMA-IR (an insulin-resistance index from fasting glucose and insulin) in obese women with PCOS (Tabrizi et al., 2020); overweight women showed no glucose or insulin difference (Montelius et al., 2014). Net reading: benefit shown only with calorie restriction in PCOS.
Magnitude: Fasting insulin fell by 5.4 vs 1.2 µU/mL over 12 weeks in obese women with PCOS.
Lower Total and Low-Density Lipoprotein Cholesterol ⚠️ Conflicted
Over 12 weeks, thylakoids lowered total and low-density lipoprotein (LDL, “bad”) cholesterol versus placebo in overweight women (Montelius et al., 2014). Added to training, they gave no metabolic benefit beyond exercise alone (Razi et al., 2026). Net reading: a small lipid benefit is unconfirmed.
Magnitude: Direction only: total and LDL cholesterol fell statistically significantly more than with placebo at 5 g/day for 12 weeks in overweight women; the openly available literature reports no absolute between-group figure.
Lower Testosterone in Women With PCOS
In one 12-week RCT, obese women with PCOS on calorie restriction had a greater fall in total testosterone with thylakoids than with placebo (Tabrizi et al., 2020). The difference held after adjusting for weight change, but rests on one small trial; all participants used oral contraceptives.
Magnitude: Total testosterone fell by 0.06 vs 0.03 ng/mL over 12 weeks under calorie restriction in obese women with PCOS.
Speculative 🟨
Favorable Gut Microbiota Shifts
Three months of thylakoids increased total gut bacteria and the Bacteroides fragilis group in volunteers (Stenblom et al., 2016). Bacterial composition is an unvalidated marker without clinical outcome data.
Lower Gut Endotoxin and Higher Nerve-Growth Protein
In women with PCOS, lipopolysaccharide (LPS, bacterial fragments leaking from the gut) fell and brain-derived neurotrophic factor (BDNF, a nerve-growth protein) rose versus placebo (Nikrad et al., 2023). Both are unvalidated biomarkers.
Anti-Inflammatory and Antioxidant Effects
A thylakoid extract reduced colitis (colon inflammation) and paw swelling in rats and dampened human white-blood-cell activity in vitro (Beaupré et al., 2020). Human oxidative-stress markers did not differ from placebo (Nikrad et al., 2023).
Cellular Energy Supply From Engineered Nanothylakoids
Coated nanothylakoids injected into mouse joints made cellular energy molecules under light and slowed osteoarthritis (Chen et al., 2022). The basis is animal-only and unrelated to oral supplements.
Benefit-Modifying Factors
- Genetic polymorphisms: no gene variant has been studied for thylakoid response. Variants in the GLP1R gene (which encodes the GLP-1 receptor) alter responses to GLP-1 drugs and could plausibly modify thylakoid-driven satiety, but this is untested.
- Baseline biomarkers: in the meta-analysis (Nikrad et al., 2025), hunger reduction was clearest when baseline hunger ratings were below 45 mm, and fullness gains when baseline fullness exceeded 45 mm. Greater insulin resistance at baseline preceded the larger insulin improvements seen in PCOS.
- Sex: most trials enrolled women, in whom sweet and chocolate cravings fell. In a mixed-sex trial (Rebello et al., 2015), men trended toward eating 126 kcal less at the next meal, while women did not.
- Pre-existing conditions: women with PCOS on calorie restriction showed the largest weight and insulin effects. People with high emotional-eating scores showed stronger craving reductions (Stenblom et al., 2015). Conditions limiting fat digestion, such as pancreatic insufficiency (low digestive-enzyme output), may blunt the mechanism.
- Age: most trials enrolled adults 18–65; only small registered studies admitted people up to 70, without published results. Benefit data beyond 65 are lacking, where slower stomach emptying and lower appetite may change the balance.
- Meal composition: the mechanism requires dietary fat; effects were shown with mixed or fat-containing meals. Very low-fat meals offer little substrate for the delayed-digestion signal.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: harms appear only as sporadic mild events in small, short placebo-controlled trials that were not designed to detect adverse events.
Medium 🟥 🟥
No risk reaches Medium: no single trial or observational dataset documents a thylakoid-attributable clinical adverse event; the available signals are short-term glucose readings and mechanistic concerns.
Low 🟥
Higher Blood Glucose After Carbohydrate-Rich Meals
A single 5 g dose raised 2-hour post-meal glucose versus placebo in overweight adults (Rebello et al., 2015); after a carbohydrate-rich breakfast, glucose stayed higher from 90 minutes, which the authors framed as preventing a post-meal dip below baseline (Stenblom et al., 2013). Twelve-week glucose was unchanged.
Magnitude: Direction only: glucose ran higher 90–120 minutes after carbohydrate-rich meals; the trials report statistical significance but no absolute between-condition figure in their text.
Speculative 🟨
Vitamin K Interference With Warfarin
Thylakoid membranes carry vitamin K1, abundant in spinach. A concentrated extract could blunt anticoagulants (blood thinners) that block vitamin K recycling, such as warfarin; the basis is mechanistic, untested in cases or trials.
Oxalate Load and Kidney Stones
Spinach is among the richest dietary oxalate sources, and the oxalate content of extracts is unpublished. Oxalate binds calcium to form kidney stones in susceptible people; the basis is mechanistic.
Gout Flares From Spinach Purines
Spinach contains purines, which can trigger gout (painful joint inflammation from uric acid crystals) in predisposed people, per a spinach monograph. Purine content of thylakoid extracts is unpublished; the basis is mechanistic.
Reduced Absorption of Fat-Soluble Nutrients or Medicines
Slower fat digestion could lower uptake of fat-soluble vitamins or fat-dependent medicines. Humans showed no steatorrhea (fatty stools) (Stenblom et al., 2016); rats absorbed two poorly water-soluble drugs normally (Saito et al., 2019).
Reduced Absorption of Mineral-Binding Antibiotics
A thylakoid-rich extract supplying about 130 mg calcium per 5 g cut ciprofloxacin (a mineral-binding antibiotic) exposure by 60% in rats (Saito et al., 2019). Human data are absent.
Contaminants: Heavy Metals and Nitrate
Spinach accumulates cadmium, lead and nitrate. The manufacturer uses a citric-acid step to bind metals, but independent batch testing is not public; the concern rests on crop biology, not reported cases.
Allergic Reactions
Spinach allergy is rare but can cause urticaria (hives) and angioedema (deep tissue swelling), with cross-reactivity to beet and chard, per a spinach monograph. No thylakoid reaction is reported; the basis is isolated spinach reports.
Slower Stomach Emptying and Bloating
In rats, thylakoids slowed stomach emptying and gut transit (Stenblom et al., 2016). In people this could cause fullness or bloating, particularly with gastroparesis (delayed stomach emptying); human data are absent.
Under-Eating and Muscle Loss
Appetite suppression could lower protein intake and speed muscle loss, especially after 65. In young women with PCOS, fat-free mass fell equally with thylakoids and placebo (Tabrizi et al., 2020); the basis is mechanistic.
Light Sensitivity From Chlorophyll Breakdown Products
Degraded chlorophyll yields pheophorbides, which caused phototoxic (sun-triggered) skin reactions with some algae supplements. Poorly stored, brown thylakoid powders could carry these; the basis is mechanistic, with no reports for thylakoids.
Risk-Modifying Factors
- Genetic polymorphisms: VKORC1 (the vitamin K recycling enzyme) and CYP2C9 (a warfarin-clearing liver enzyme) variants heighten warfarin users’ sensitivity to vitamin K swings. Rare AGXT (a liver oxalate-processing enzyme) variants cause primary hyperoxaluria (excess oxalate production), raising stone risk.
- Baseline biomarkers: an unstable international normalized ratio (INR, a clotting-time test used to dose warfarin), high 24-hour urinary oxalate, low estimated glomerular filtration rate (eGFR, kidney filtering capacity) or low vitamin D mark people more exposed to theoretical risks.
- Sex: trial safety data come mostly from women. Pregnancy and breastfeeding are unstudied; spinach at food amounts is safe, but concentrated extracts are not evaluated.
- Pre-existing conditions: prior calcium-oxalate kidney stones, fat malabsorption (celiac disease, chronic pancreatitis, bariatric surgery), gastroparesis, and diabetes treated with insulin or sulfonylureas (drugs that force insulin release) raise the relevance of the speculative risks.
- Age: adults over 65 more often take warfarin, have slower stomach emptying and reduced kidney function, and risk muscle loss when appetite falls; only small pilots admitted people up to 70, without published safety data.
Key Interactions & Contraindications
Prescription drugs:
- Vitamin K antagonist anticoagulants (blood thinners that block vitamin K recycling: warfarin, acenocoumarol, phenprocoumon): caution. Added vitamin K1 could lower INR and anticoagulant effect, raising clot risk. Mitigation: stable daily intake and an INR check within 1–2 weeks of starting or stopping.
- GLP-1 receptor agonists (injectable drugs mimicking GLP-1: semaglutide, tirzepatide, liraglutide): monitor. Additive appetite suppression and slower stomach emptying may worsen nausea and under-eating. Mitigation: adding thylakoids only on a stable drug dose, tracking protein intake and weight.
- Glucose-lowering drugs (insulin, glipizide, glimepiride): monitor. Thylakoids shift post-meal glucose and insulin timing, which could alter glucose readings. Mitigation: glucose checks for 1–2 weeks after starting.
- Fat-dependent drugs with a narrow safe dose range (cyclosporine, isotretinoin, amiodarone): caution, theoretical. Slower fat digestion might lower absorption and effect. Mitigation: dosing at least 2 hours apart.
- Mineral-binding antibiotics (fluoroquinolones and tetracyclines: ciprofloxacin, levofloxacin, doxycycline): caution. The extract’s calcium cut ciprofloxacin absorption by 60% in rats (Saito et al., 2019), risking treatment failure. Mitigation: taking the antibiotic 2 hours before or 6 hours after thylakoids.
Over-the-counter medications:
- Orlistat (Alli, 60 mg): caution. Both slow fat digestion; combined use may raise fatty stools and fat-soluble vitamin loss. Mitigation: avoiding co-administration or supplementing vitamins A, D, E and K at bedtime.
- Fiber laxatives and bulking agents (psyllium, methylcellulose): monitor. Additive fullness and slower transit may cause bloating. Mitigation: separating doses by 2 hours and increasing fluid intake.
Supplements:
- Vitamin K supplements (K1 phylloquinone, K2 menaquinone-7): caution in warfarin users. Additive vitamin K load reduces anticoagulant effect. Mitigation: keeping total vitamin K intake constant and monitoring INR.
- Fat-soluble supplements (fish oil, vitamin D3, coenzyme Q10, curcumin): monitor, theoretical. Absorption may fall if taken with the thylakoid dose. Mitigation: taking them at a different meal.
- Calcium, magnesium and zinc: monitor. Spinach oxalate can bind these minerals and reduce absorption. Mitigation: separating mineral supplements by 2 hours.
- Additive appetite and glucose agents (glucomannan, berberine, green tea extract): monitor. Additive satiety or glucose effects may cause under-eating or unexpected glucose shifts. Mitigation: adding one agent at a time for 2–4 weeks.
Other interventions:
- Very low-fat diets: reduced effect, not a safety issue. Without dietary fat, the delayed-digestion signal is weak. Mitigation: dosing with a meal containing some fat, as in all trials.
- Bariatric surgery: caution. Altered anatomy and malabsorption make benefit unpredictable and vitamin losses more likely. Mitigation: vitamin-level monitoring by the surgical team.
Populations who should avoid Thylakoids:
- Pregnant or breastfeeding women (no safety data for concentrated extracts)
- Warfarin or other vitamin K antagonist users with unstable INR (fluctuating outside the 2.0–3.0 target range) or without access to INR monitoring
- People with prior calcium-oxalate kidney stones, primary or enteric hyperoxaluria (excess oxalate absorbed from the gut when fat is poorly digested), or eGFR below 30 mL/min/1.73 m² (chronic kidney disease stage 4–5)
- People with known spinach, beet or chard allergy
- People with an active eating disorder or a body mass index (BMI, weight relative to height) below 18.5 kg/m²
- Children and adolescents under 18 (not studied)
Risk Mitigation Strategies
- Kidney-stone precaution: people at elevated stone risk (family history, low urine volume) take thylakoids with a calcium-containing meal, keep fluid intake above 2.5 L/day, and check 24-hour urinary oxalate after 4–8 weeks, limiting oxalate-driven stone formation.
- Anticoagulant safety: warfarin users keep the daily dose constant and check INR 1–2 weeks after starting, changing or stopping, preventing loss of anticoagulant effect from added vitamin K.
- Glucose tracking: people using glucose-lowering drugs or prone to post-meal highs check 2-hour post-meal glucose for 1–2 weeks, detecting the higher glucose seen after carbohydrate-rich meals.
- Medication and nutrient spacing: separating fat-dependent medicines, fat-soluble vitamins and minerals from the thylakoid dose by at least 2 hours, and mineral-binding antibiotics 2 hours before or 6 hours after it, reduces absorption loss.
- Protein and lean-mass protection: keeping protein at 1.2–1.6 g/kg/day and resistance training 2–3 times weekly counteracts muscle loss when appetite and intake fall, especially over 65.
- Quality control: choosing green (not olive-brown), sealed, in-date powder from suppliers publishing heavy-metal and microbial testing limits contaminant and degraded-chlorophyll exposure.
- Gradual start: beginning with 2.5 g/day for 1 week before 5 g/day reduces fullness and bloating from slower stomach emptying.
Therapeutic Protocol
- Standard dose (Lund protocol): 5 g/day of standardized spinach thylakoid extract (Appethyl) was used in almost all trials by the Lund University group of Charlotte Erlanson-Albertsson; the meta-analysis also found effects at 7.4 g/day (Nikrad et al., 2025).
- Timing, appetite-control approach: the Lund trials gave the dose once daily before breakfast to curb hunger and cravings through the day; Pennington Biomedical Research Center (Frank Greenway) gave it just before lunch (Rebello et al., 2015).
- Timing, metabolic approach: Tabriz University trials (Mahdieh Abbasalizad Farhangi) combined 5 g/day, 30 minutes before lunch, with a 500 kcal/day calorie deficit (Tabrizi et al., 2020); exercise trials used the same timing alongside training (Saeidi et al., 2023).
- Competing approaches: thylakoids alone for appetite, thylakoids with calorie restriction, and thylakoids with exercise are the three tested strategies; prescription GLP-1 drugs act on the same fullness pathway with far larger, but costlier, effects.
- Administration: powder is stirred into cold or room-temperature water, juice or yogurt with a meal containing some fat; hot drinks and cooking are avoided because heat degrades function.
- Half-life: thylakoids are not absorbed, so no blood half-life exists; the satiety effect lasts roughly 2–4 hours after a meal, with craving effects reported through the day.
- Single vs split dosing: trials used one daily dose; splitting 5 g across two fat-containing meals is a plausible but untested variant.
- Genetic polymorphisms: no variant guides dose; warfarin users with sensitive VKORC1 or CYP2C9 variants keep doses constant.
- Sex: women showed reduced sweet cravings; men trended toward lower savory intake. No sex-specific dose exists.
- Age: published trials covered ages 18–65 (registered pilots up to 70); adults over 65 lack data and may start at 2.5 g/day given slower stomach emptying and appetite loss risk.
- Baseline biomarkers: people with fasting insulin or HOMA-IR above optimal ranges showed the clearest metabolic gains when thylakoids accompanied weight loss.
- Pre-existing conditions: PCOS with obesity showed the largest effects; kidney-stone risk, fat malabsorption and anticoagulant use call for the precautions above.
Discontinuation & Cycling
- Duration: trials lasted a single day to 12 weeks, one unpublished study 24 weeks; thylakoids are used as an ongoing daily aid during weight-management phases rather than lifelong, and long-term use is unstudied.
- Withdrawal effects: none reported; appetite effects disappear within hours of the last dose because nothing accumulates in the body.
- Tapering: not required, as there is no dependence or rebound mechanism; stopping at once is the norm in trials.
- Cycling: not studied. The meta-analysis (Nikrad et al., 2025) found hunger effects clearest in interventions under 8 weeks, hinting at possible attenuation; periodic breaks to reassess benefit are an untested option.
Sourcing and Quality
- Standardized extract: Appethyl, the extract used in most trials, is standardized to inhibit lipase activity by 50–75% in the laboratory; generic “spinach leaf extract” is usually not tested for this.
- Batch variability: EFSA noted thylakoid content ranging from 52.6% to 85.9% by weight across Appethyl batches (EFSA Panel, 2023), so the same dose can deliver different amounts of active membrane.
- Color as a quality marker: functional thylakoid powder is bright green; olive-brown color signals chlorophyll breakdown and lost lipase inhibition from heat, moisture or age.
- Storage: the powder absorbs moisture and degrades at higher humidity; sealed, dry, cool storage and the manufacturer’s stated 24-month shelf life apply.
- Not to be confused: “red spinach extract” (a nitrate source for exercise) and spinach extracts standardized to ecdysterone (a plant steroid marketed for muscle) are different products without thylakoid activity.
- Testing: third-party certification (NSF International or USP, independent supplement-testing bodies) is rare for thylakoid products; a certificate of analysis for heavy metals, microbes and pesticides from the supplier is the practical substitute.
- Brands: products labeled as containing Appethyl (Greenleaf Medical AB, Sweden) match the trial material; Life Extension sells a thylakoid-containing product. Thykamine is a pharmaceutical candidate, not a retail supplement.
Practical Considerations
- Time to effect: reduced hunger appears within 2 hours of a dose; weight or body-fat changes, where seen, took 12 weeks alongside calorie restriction.
- Common pitfalls: dosing with fat-free meals, mixing into hot drinks, buying non-standardized spinach extracts, and expecting weight loss without a calorie deficit are the main reasons for disappointment.
- Regulatory status: sold as a food or dietary supplement in the European Union and U.S., without U.S. Food and Drug Administration (FDA) efficacy review; spinach is generally recognized as safe. EFSA, with no revenue at stake, declined an Appethyl weight-loss claim (EFSA Panel, 2023).
- Cost and access: thylakoid extracts are moderately priced over-the-counter supplements and not exceptionally expensive or hard to obtain.
- Research funding: competing prescription GLP-1 drugs cost far more, yet insurers and health systems do not reimburse or fund supplement trials; nearly all thylakoid research is funded by the manufacturer or small academic grants, a structural bias in the evidence.
Interaction with Foundational Habits
- Sleep: no direct interaction. Indirectly, short sleep raises ghrelin and cravings, the appetite pathway thylakoids act on in daytime trials. Evening dosing is unstudied; morning or midday dosing matches the trials and avoids fullness at bedtime.
- Nutrition: potentiating, with conditions. The mechanism depends on dietary fat, so meals need some fat (olive oil, eggs, nuts). Thylakoids may modestly lower uptake of fat-soluble nutrients, and spinach oxalate may bind calcium; pairing with calcium-containing foods and varied vegetables offsets both.
- Exercise: neutral to mildly additive. In obese men doing high-intensity functional training (HIFT, CrossFit-style circuits), thylakoids added little beyond training for fat loss (Razi et al., 2026), with mixed reports on insulin and lipids. Dosing 30 minutes before a post-workout meal fits the trial protocol; no blunting of training adaptation has been reported.
- Stress management: indirect. People with high emotional-eating scores showed the largest craving reductions (Stenblom et al., 2015), suggesting relevance to stress-driven snacking via GLP-1 reward signaling; no effect on cortisol has been measured.
Monitoring Protocol & Defining Success
Baseline testing: before starting, body weight, waist circumference and body composition are recorded, along with fasting glucose, insulin, glycated hemoglobin (HbA1c, average blood sugar over about 3 months) and a lipid panel. Warfarin users add an INR, and people at elevated kidney-stone risk add eGFR and a 24-hour urine oxalate. A one-week diary of 0–100 hunger and craving ratings sets a subjective baseline.
Ongoing monitoring: weight and appetite ratings are tracked weekly for the first 4 weeks, then monthly. Fasting glucose, insulin, HbA1c and lipids are repeated at 12 weeks, then every 6–12 months while use continues. Warfarin users recheck INR 1–2 weeks after starting or stopping; those at stone risk recheck urinary oxalate at 4–8 weeks. Success means lower hunger and cravings within 4 weeks and, where weight loss is the aim, added loss by 12 weeks.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Body weight and waist circumference | Waist below 80 cm (women) or 94 cm (men); weight trend toward personal goal | Primary outcome of appetite control | Same scale, morning, fasted; conventional waist cut-offs are 88 cm and 102 cm |
| Body composition | No established target; track change from own baseline (stable lean mass, falling fat mass) | Confirms loss is fat, not muscle | Dual-energy X-ray absorptiometry (DXA, a body-composition scan) or bioimpedance, same device each time |
| Fasting glucose | 75–90 mg/dL | Tracks glucose effects | 10–12-hour fast; conventional normal range is below 100 mg/dL |
| Fasting insulin and HOMA-IR | Insulin 2–6 µIU/mL; HOMA-IR below 1.0 | Tracks insulin sensitivity | Drawn with fasting glucose; conventional labs flag insulin only above about 25 µIU/mL |
| HbA1c | 4.8–5.3% | Longer-term glucose control | No fasting needed; conventional normal is below 5.7% |
| LDL cholesterol and apolipoprotein B | LDL below 100 mg/dL; apolipoprotein B below 80 mg/dL | Tracks the reported lipid effect | Apolipoprotein B counts artery-clogging particles; fasting preferred; conventional LDL target below 130 mg/dL |
| INR (warfarin users only) | Individual target, usually 2.0–3.0 | Detects vitamin K interference | Checked 1–2 weeks after any change in thylakoid use |
| 24-hour urinary oxalate (elevated stone risk only) | Below 25 mg/day | Detects added oxalate load | Paired with urine volume and calcium; conventional upper limit about 40 mg/day |
| eGFR (elevated stone risk or kidney disease only) | Above 90 mL/min/1.73 m² | Kidney function context for oxalate | Paired with creatinine and cystatin C; conventional threshold is 60 mL/min/1.73 m² or above |
| 25-hydroxy vitamin D | 40–60 ng/mL | Screens for reduced fat-soluble vitamin uptake | Conventional sufficiency threshold is 20–30 ng/mL; recheck at 12 weeks |
Qualitative markers:
- Hunger between meals and urge for sweet, salty or fatty snacks (0–100 ratings)
- Ease of keeping to planned meals without snacking
- Digestive comfort: bloating, fullness, stool changes
- Energy levels and training performance during a calorie deficit
- Emotional or stress-related eating episodes per week
Emerging Research
- Ongoing trials: no thylakoid trial was recruiting or active on ClinicalTrials.gov as of September 2026; the registered studies below are completed or terminated.
- Terminated prediabetes trial: a 26-week triple-blind RCT of 5 g/day Appethyl in 82 overweight adults with prediabetes (primary endpoint fasting glucose) at the University of Copenhagen (NCT05095038) stopped in 2023 when the manufacturer suspended funding; unpublished results could strengthen or weaken the metabolic case.
- Glucose tolerance dosing study: a completed Swedish study comparing two thylakoid doses during an oral glucose tolerance test in 21 participants (NCT02702245) has no published results; it could clarify the post-meal glucose signal.
- Early metabolic pilot: a 2010 Swedish pilot adding thylakoids to calorie restriction in 20 overweight-to-obese men aged 40–70, listed under metabolic syndrome (a cluster of excess waist, high blood pressure, glucose and blood fats) (NCT02687295), is registered as completed without posted results.
- Exercise combination trials: overlapping Iranian cohorts of 60–68 obese men gave mixed results: thylakoids augmented training effects on insulin resistance and lipids in one report (Saeidi et al., 2023) but showed no metabolic superiority over training alone in another (Razi et al., 2026); a larger independent trial could settle the add-on question.
- Weight-maintenance replication: EFSA, a regulator with no revenue at stake, noted that a 24-week weight-maintenance benefit had not been replicated (EFSA Panel, 2023); an independent maintenance trial would be decisive in either direction.
- Anti-inflammatory drug development: a phase 2 trial of topical Thykamine in 162 adults with atopic dermatitis (NCT03540043) met its primary endpoint; a phase 2 enema trial in 34 patients with ulcerative colitis (chronic inflammation of the colon lining) (NCT01149707) completed; laboratory data suggest broad suppression of chemokines (immune-cell-attracting signals) (Lynde et al., 2025).
- “Borrowed photosynthesis” nanomedicine: engineered nanothylakoids restored cellular energy in mouse osteoarthritis (Chen et al., 2022) and corneal cells in dry-eye models (Xing et al., 2026); relevant to tissue aging, but injected or topical, light-dependent and far from human use.
Conclusion
Thylakoids are the light-capturing membranes of green leaves, concentrated from spinach into a powder that slows fat digestion in the gut and strengthens the body’s own fullness signals. For health-focused adults working on appetite and body composition, the most consistent finding is a short-lived drop in hunger and snack cravings after a dose taken with a meal. Evidence that this adds up to meaningful, lasting weight loss is mixed: some trials, especially alongside a calorie-reduced diet, show extra fat loss, while others show none, and a European food-safety panel found the weight evidence insufficient. Improvements in insulin, cholesterol and hormone levels appear mainly where extra weight is lost, and gut-bacteria or anti-inflammatory effects remain early findings. A skin cream made from thylakoids is a separate drug product.
Known risks are low in the short studies available, but safety has not been studied beyond a few months, and theoretical concerns involve vitamin K with blood thinners, a stone-forming compound in spinach for people prone to kidney stones, and reduced uptake of vitamins absorbed with fat. The evidence base is small, and much of it comes from the extract’s developers and its manufacturer, with a supplement retailer also promoting it; the regulator that rejected the weight claim has no commercial stake. Independent trials have partly confirmed and partly contradicted the developers’ results.